Is cannabis neurotoxic for the healthy brain? A meta-analytical review of structural brain alterations in non-psychotic users

Psychiatry and Clinical Neurosciences

Volumn 67, Issue 7, 2013, Pages 483-492

  Rocchetti, Matteo ^a,b   Crescini, Alessandra ^c   Borgwardt, Stefan ^d   Caverzasi, Edgardo ^b   Politi, Pierluigi ^b   Atakan, Zerrin ^a   Fusar Poli, Paolo ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d UNIVERSITY OF BASEL   (Switzerland)

Author keywords

amygdala; cannabis; hippocampus; neuroimaging; psychosis

Indexed keywords

CANNABIS;

BRAIN FUNCTION; CANNABIS SMOKING; GRAY MATTER; HIPPOCAMPUS; HUMAN; HYPOTHESIS; META ANALYSIS; NEUROIMAGING; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; WHITE MATTER;

AMYGDALA; CANNABIS; HIPPOCAMPUS; NEUROIMAGING; PSYCHOSIS;

BRAIN; CANNABIS; HUMANS; MARIJUANA SMOKING; NEUROTOXICITY SYNDROMES; PERSONAL SATISFACTION;

EID: 84886953407     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/pcn.12085     Document Type: Review

References (57)

1. Crippa JA, Derenusson GN, Ferrari TB, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: A preliminary report. J. Psychopharmacol. 2011; 25: 121-130.
2. Crippa JA, Zuardi AW, Martin-Santos R, et al. Cannabis and anxiety: A critical review of the evidence. Hum. Psychopharmacol. 2009; 24: 515-523.
3. Fusar-Poli P, Crippa JA, Bhattacharyya S, et al. Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch. Gen. Psychiatry 2009; 66: 95-105.
4. Fusar-Poli P, Allen P, Bhattacharyya S, et al. Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol. Int. J. Neuropsychopharmacol. 2010; 13: 421-432.
5. Bhattacharyya S, Morrison PD, Fusar-Poli P, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 2010; 35: 764-774.
6. Bhattacharyya S, Fusar-Poli P, Borgwardt S, et al. Modulation of mediotemporal and ventrostriatal function in humans by Delta9- tetrahydrocannabinol: A neural basis for the effects of Cannabis sativa on learning and psychosis. Arch. Gen. Psychiatry 2009; 66: 442-451.
7. Bhattacharyya S, Crippa JA, Allen P, et al. Induction of psychosis by delta 9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Arch. Gen. Psychiatry 2012; 69: 27-36.
8. Lorenzetti V, Lubman DI, Whittle S, Solowij N, Yucel M,. Structural MRI findings in long-term cannabis users: What do we know? Subst. Use Misuse 2010; 45: 1787-1808.
9. Rapp C, Bugra H, Riecher-Rossler A, Tamagni C, Borgwardt S,. Effects of cannabis use on human brain structure in psychosis: A systematic review combining in vivo structural neuroimaging and post mortem studies. Curr. Pharm. Des. 2012; 18: 5070-5080.
10. Fusar-Poli P, Radua J, McGuire P, Borgwardt S,. Neuroanatomical maps of psychosis onset: Voxel-wise meta-analysis of antipsychotic-naive VBM studies. Schizophr. Bull. 2012; 38: 1297-1307.
11. Hermann D, Schneider M,. Potential protective effects of cannabidiol on neuroanatomical alterations in cannabis users and psychosis: A critical review. Curr. Pharm. Des. 2012; 18: 4897-4905.
12. Jager G, Ramsey NF,. Long-term consequences of adolescent cannabis exposure on the development of cognition, brain structure and function: An overview of animal and human research. Curr Drug Abuse Rev 2008; 1: 114-123.
13. Martin-Santos R, Fagundo AB, Crippa JA, et al. Neuroimaging in cannabis use: A systematic review of the literature. Psychol. Med. 2010; 40: 383-398.
14. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P,. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ 2009; 339: b2535.
15. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF,. Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. QUOROM Group. Br. J. Surg. 2000; 87: 1448-1454.
16. Courchesne E, Chisum HJ, Townsend J, et al. Normal brain development and aging: Quantitative analysis at in vivo MR imaging in healthy volunteers. Radiology 2000; 216: 672-682.
17. Borenstein MHL, Higgins J, Rothstein H,. Comprehensive Meta-Analysis Version 2. Biostat, Englewood, NJ, 2005.
18. Hedges L, Holkin I,. Statistical Methods for Meta-Analysis. Academic Press, New York, 1985.
19. Fleiss JL,. The statistical basis of meta-analysis. Stat. Methods Med. Res. 1993; 2: 121-145.
20. Cooper H, Hedges L, Valentine J,. Handbook of Research Synthesis and Meta-Analysis. Russell Sage Foundation, New York, 2009.
21. Paulson JF, Bazemore SD,. Prenatal and postpartum depression in fathers and its association with maternal depression: A meta-analysis. JAMA 2010; 303: 1961-1969.
22. Lipsey M, Wilson D,. Practical Meta-Analysis. Sage Publications, Thousand Oaks, CA, 2000.
23. Egger M, Davey Smith G, Schneider M, Minder C,. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
24. Orwin R,. A fail-safe N for effect size in meta-analysis. J Edu Stat 1983; 8: 157-159.
25. Duval S, Tweedie R,. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000; 56: 455-463.
26. Batalla A, Soriano-Mas C, Lopez-Sola M, et al. Modulation of brain structure by catechol-O-methyltransferase Val(158) Met polymorphism in chronic cannabis users. Addict. Biol. 2013. doi: 10.1111/adb.12027
27. Schacht JP, Hutchison KE, Filbey FM,. Associations between cannabinoid receptor-1 (CNR1) variation and hippocampus and amygdala volumes in heavy cannabis users. Neuropsychopharmacology 2012; 37: 2368-2376.
28. Zalesky A, Solowij N, Yucel M, et al. Effect of long-term cannabis use on axonal fibre connectivity. Brain 2012; 135: 2245-2255.
29. Ashtari M, Avants B, Cyckowski L, et al. Medial temporal structures and memory functions in adolescents with heavy cannabis use. J. Psychiatr. Res. 2011; 45: 1055-1066.
30. Cousijn J, Wiers RW, Ridderinkhof KR, van den Brink W, Veltman DJ, Goudriaan AE,. Grey matter alterations associated with cannabis use: Results of a VBM study in heavy cannabis users and healthy controls. Neuroimage 2012; 59: 3845-3851.
31. Lopez-Larson MP, Bogorodzki P, Rogowska J, et al. Altered prefrontal and insular cortical thickness in adolescent marijuana users. Behav. Brain Res. 2011; 220: 164-172.
32. McQueeny T, Padula CB, Price J, Medina KL, Logan P, Tapert SF,. Gender effects on amygdala morphometry in adolescent marijuana users. Behav. Brain Res. 2011; 224: 128-134.
33. Mata I, Perez-Iglesias R, Roiz-Santianez R, et al. Gyrification brain abnormalities associated with adolescence and early-adulthood cannabis use. Brain Res. 2010; 1317: 297-304.
34. Yucel M, Solowij N, Respondek C, et al. Regional brain abnormalities associated with long-term heavy cannabis use. Arch. Gen. Psychiatry 2008; 65: 694-701.
35. Medina KL, Nagel BJ, Park A, McQueeny T, Tapert SF,. Depressive symptoms in adolescents: Associations with white matter volume and marijuana use. J. Child Psychol. Psychiatry 2007; 48: 592-600.
36. Medina KL, Schweinsburg AD, Cohen-Zion M, Nagel BJ, Tapert SF,. Effects of alcohol and combined marijuana and alcohol use during adolescence on hippocampal volume and asymmetry. Neurotoxicol. Teratol. 2007; 29: 141-152.
37. Delisi LE, Bertisch HC, Szulc KU, et al. A preliminary DTI study showing no brain structural change associated with adolescent cannabis use. Harm. Reduct. J. 2006; 3: 17-22.
38. Tzilos GK, Cintron CB, Wood JB, et al. Lack of hippocampal volume change in long-term heavy cannabis users. Am. J. Addict. 2005; 14: 64-72.
39. Block RI, O'Leary DS, Ehrhardt JC, et al. Effects of frequent marijuana use on brain tissue volume and composition. Neuroreport 2000; 11: 491-496.
40. Higgins JP, Thompson SG,. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002; 21: 1539-1558.
41. Becker B, Wagner D, Gouzoulis-Mayfrank E, Spuentrup E, Daumann J,. Altered parahippocampal functioning in cannabis users is related to the frequency of use. Psychopharmacology (Berl) 2010; 209: 361-374.
42. Benes FM, Turtle M, Khan Y, Farol P,. Myelination of a key relay zone in the hippocampal formation occurs in the human brain during childhood, adolescence, and adulthood. Arch. Gen. Psychiatry 1994; 51: 477-484.
43. Sturman DA, Moghaddam B,. The neurobiology of adolescence: Changes in brain architecture, functional dynamics, and behavioral tendencies. Neurosci. Biobehav. Rev. 2011; 35: 1704-1712.
44. Mackie K,. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb. Exp. Pharmacol. 2005; 168: 299-325.
45. Chan GC, Hinds TR, Impey S, Storm DR,. Hippocampal neurotoxicity of Delta9-tetrahydrocannabinol. J. Neurosci. 1998; 18: 5322-5332.
46. Hoffman AF, Lupica CR,. Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus. J. Neurosci. 2000; 20: 2470-2479.
47. Kim D, Thayer SA,. Cannabinoids inhibit the formation of new synapses between hippocampal neurons in culture. J. Neurosci. 2001; 21: RC146.
48. Carlson G, Wang Y, Alger BE,. Endocannabinoids facilitate the induction of LTP in the hippocampus. Nat. Neurosci. 2002; 5: 723-724.
49. Solowij N, Battisti R,. The chronic effects of cannabis on memory in humans: A review. Curr. Drug Abuse Rev. 2008; 1: 81-98.
50. Squire LR, Stark CE, Clark RE,. The medial temporal lobe. Annu. Rev. Neurosci. 2004; 27: 279-306.
51. Wagner D, Becker B, Gouzoulis-Mayfrank E, Daumann J,. Interactions between specific parameters of cannabis use and verbal memory. Prog. Neuropsychopharmacol Biol. Psychiatry 2010; 34: 871-876.
52. Pope HG Jr, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D,. Neuropsychological performance in long-term cannabis users. Arch. Gen. Psychiatry 2001; 58: 909-915.
53. Dhikav V, Anand K,. Potential predictors of hippocampal atrophy in Alzheimer's disease. Drugs Aging 2011; 28: 1-11.
54. Potter DJ, Clark P, Brown MB,. Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: Implications for psychoactivity and pharmacology. J. Forensic Sci. 2008; 53: 90-94.
55. Demirakca T, Sartorius A, Ende G, et al. Diminished gray matter in the hippocampus of cannabis users: Possible protective effects of cannabidiol. Drug Alcohol Depend. 2011; 114: 242-245.
56. Cascini F, Aiello C, Di Tanna G,. Increasing delta-9-tetrahydrocannabinol (Delta-9-THC) content in herbal cannabis over time: Systematic review and meta-analysis. Curr Drug Abuse Rev 2012; 5: 32-40.
57. Cheetham A, Allen NB, Whittle S, Simmons JG, Yucel M, Lubman DI,. Orbitofrontal volumes in early adolescence predict initiation of cannabis use: A 4-year longitudinal and prospective study. Biol. Psychiatry 2012; 71: 684-692.